Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.

Clinical breast cancer - 1 Feb 2015

Akashi-Tanaka Sadako, Watanabe Chie, Takamaru Tomoko, Kuwayama Takashi, Ikeda Murasaki, Ohyama Hiroto, Mori Miki, Yoshida Reiko, Hashimoto Rikako, Terumasa Sawada, Enokido Katsutoshi, Hirota Yuko, Okuyama Hiromi, Nakamura Seigo

Abstract excerpt

BACKGROUND: To provide optimal treatment of heterogeneous triple negative breast cancer (TNBC), we need biomarkers that can predict the chemotherapy response. PATIENTS AND METHODS: We retrospectively investigated BRCAness in 73 patients with breast cancer who had been treated with taxane- and/or anthracycline-based neoadjuvant chemotherapy (NAC). Using multiplex, ligation-dependent probe amplification on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Ductal, Breast

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Neoadjuvant Therapy

Share to Taxoids

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 25445419
DOI: 10.1016/j.clbc.2014.08.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.PMID 25445419Read ↗

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Semantic proximity Read ↗

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.Semantic proximity Read ↗

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisSemantic proximity Read ↗

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell LinesSemantic proximity Read ↗

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.Semantic proximity Read ↗

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancersSemantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxaneSemantic proximity Read ↗

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriersSemantic proximity Read ↗

Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.Semantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.